CFRX - ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market
- CFRX is developing a medicine to treat bacterial infections without using an antibiotic.
- Phase 2 trials have shown outstanding data against MRSA infections, and reduced hospital time.
- The company has decent cash, but may need more.
For further details see:
ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market